Aadil Najeed, Senior Resident of Government Medical College Srinagar, shared a post on LinkedIn:
“Practice-changing evidence in breast radiotherapy
The UNICANCER HypoG-01 phase III trial evaluated hypofractionated locoregional RT in early breast cancer requiring nodal irradiation.
1265 patients
29 centres in France
Median follow-up: 4.8 years
Comparison
40 Gy / 15 fractions (3 weeks)
vs
50 Gy / 25 fractions (5 weeks)
Key findings:
Arm lymphoedema
- 23.4% (3-week RT) vs 22.2% (5-week RT)
- HR 1.02 — met non-inferiority
Toxicity
- Grade ≥3 toxicity: 8% vs 13%
- Overall safety profiles comparable
Takeaway
Hypofractionated locoregional RT (40 Gy in 15 fractions) is non-inferior to conventional 5-week RT for patients requiring nodal irradiation after breast cancer surgery.
This adds strong evidence supporting shorter treatment schedules even when regional nodes are included — improving patient convenience and resource utilisation without compromising safety.”
Other articles featuring Aadil Najeed on OncoDaily.